Available for Preorder: The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

On March 15, 2022, Drug Channels Institute will release The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. This report—our thirteenth edition—remains the most comprehensive, fact-based tool for understanding the entire U.S. drug pricing, reimbursement, and dispensing system.

12 chapters, 430+ pages, 216 exhibits, 800+ endnotes: There is nothing else available that comes close to this report.

We are providing you with the opportunity to preorder this thoroughly updated, revised, and expanded 2022 edition at special discounted prices. This means that you can be among the first to access our new report. Those who preorder will receive a download link before March 15.

CLICK HERE to download a free pre-publication overview
(including key industry trends, the Table of Contents, and a List of Exhibits).

You can pay online with all major credit cards (Visa, MasterCard, American Express, and Discover) or via PayPal. Click here to email us if you would like to pay by corporate purchase order or check.

Special preorder and launch pricing discounts will be valid through March 28, 2022.

The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers is a definitive, nonpartisan resource that includes the most current information about pharmacy dispensing channels, third-party payers, pharmacy benefit managers (PBMs), patients’ financial contributions, government regulations, and much more.

As always, we have updated all market and industry data with the most current information available, including our annual analyses of the market positions of the largest pharmacies, specialty pharmacies, and PBMs.

This 2022 edition addresses COVID-19 and its ongoing impact on the pharmacy and PBM industries. Many sections and chapters have also been expanded and/or reorganized to better cover the latest industry developments. New sections cover: pharmacies’ administration of—and profits from—COVID-19 vaccines; smaller PBMs; PBM purchasing groups and GPOs; 340b split-billing software vendors; and shakeout and consolidation within retail pharmacy. We also present a more unified outlook for specialty drugs, including specialty generics and biosimilars.Download a free report overview for more details.

The chart below illustrates the depth and breadth of the 2022 edition. The numbers indicate the report chapter that corresponds to, explains, and analyzes each channel flow.

[Click to Enlarge]

Thank you for your interest in our work. If you have any questions before purchasing a license to the report, please email me. Enjoy!